The abstract is read at the publisher; the summary is JClub's.
A CRISPR-built KAT6A–p300 fusion in an endogenous mouse AML model drives aggressive, transplantable leukemia linked to broad promoter hyperacetylation and enforced transcription initiation.
- Why it matters: Histone acetylation correlates with active transcription, but its causal downstream mechanisms in leukemia are not fully defined, especially for HAT fusion-driven dysregulation.
- What they did: The study created an endogenous mouse AML model via CRISPR-mediated chromosomal rearrangement producing a KAT6A–p300 fusion, then mapped promoter hyperacetylated domains and their effects on BAF recruitment, accessibility, and RNA polymerase II initiation.
- The result: KAT6A–p300 establishes promoter-associated hyperacetylation that recruits and remodels via the canonical BAF complex, increases promoter accessibility, and enhances RNA polymerase II recruitment, while redistributing wild-type p300 to fusion-bound loci.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.